Molecular Medicine Reports, an esteemed academic journal published by Spandidos Publications Ltd, serves as a vital platform for the dissemination of cutting-edge research in the field of molecular medicine. Established in 2008, this journal has rapidly ascended in prominence, currently positioned within the Q2 and Q3 quartiles across various critical categories including Biochemistry, Cancer Research, and Genetics, reflecting its significant impact and scholarly contributions. With an impressive Scopus ranking in multiple disciplines, including an 87th place in Oncology, it is recognized for publishing rigorous, peer-reviewed articles that bridge the gap between laboratory research and clinical applications. The journal’s commitment to advancing knowledge in molecular medicine is evident through its focus on innovative therapeutic approaches, genetic research, and oncological studies, catering to a diverse readership of researchers, professionals, and students in the biomedical field. Though not an open-access publication, it provides invaluable insights and fosters collaboration in the scientific community from its base in Athens, Greece.

Current Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.

Inflammation and Regeneration is a prominent open-access journal published by BMC, focused on the discerning fields of immunology, cell biology, and regenerative medicine. Since its establishment in 2016, the journal has provided a platform for the dissemination of high-quality research, contributing significantly to the advancement of knowledge in inflammation processes and regenerative therapies. With a remarkable impact reflected in its Q1 quartile rankings in Cell Biology and Immunology for 2023, Inflammation and Regeneration stands out as a leading resource for researchers and practitioners. The journal's commitment to open access ensures that critical findings are readily available to a global audience, fostering collaboration and innovation in the scientific community. With a Scopus ranking that places it in the top 20% of its categories, Inflammation and Regeneration serves as an essential reference for those seeking to stay at the forefront of immunological research and its applications.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Biomedical Research and Therapy is a pioneering journal published by BIOMEDPRESS, dedicated to the field of biomedical sciences. With its ISSN 2198-4093, this journal aims to disseminate high-quality research and innovative therapies that advance knowledge in biomedical research. Although it operates on a non-open access model, it provides crucial insights into various topics such as drug discovery, disease mechanisms, regenerative medicine, and clinical applications. The journal's rigorous peer-review process ensures the publication of critical findings and methodologies, making it a vital resource for researchers, practitioners, and students interested in the constantly evolving landscape of biomedical research. With converged years from 2020 to 2024 and an emerging reputation in its field, Biomedical Research and Therapy is positioned to contribute significantly to the global scientific community, enriching the discourse around therapeutic advancements and biomedical innovations.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

DERMATOLOGY, an esteemed journal published by KARGER, is a vital resource in the field of dermatological research and clinical practice. Established in 1893, with its comprehensive coverage extending to 2024, this journal has earned its place as a leading publication, holding a prestigious Q1 quartile ranking in Dermatology and ranking 15th out of 142 in the Scopus Medicine - Dermatology category, reflecting its 89th percentile standing within the discipline. The journal aims to disseminate innovative research findings, critical reviews, and clinical studies that advance the understanding of skin disorders and their treatments. While primarily available through institutional subscriptions, DERMATOLOGY remains committed to enhancing accessibility and fostering international collaboration among researchers, professionals, and students in the dermatological community. Its rigorous peer-review process guarantees the highest quality of published works, making it an essential reference for those dedicated to advancing dermatological science and improving patient care.